A year of successful cancer vaccines points to a path forward.
Results from recent clinical trials of the therapeutic vaccines sipuleucel-T (Dendreon Corp), PROSTVAC-VF-TRICOM (National Cancer Institute/BN ImmunoTherapeutics Inc) and BiovaxID (Biovest International Inc) are highlighted. These data support the further development of such vaccines, and provide guidance for the development of improved agents and protocols for the use of therapeutic vaccination to treat cancer.
Morse
Michael A
MA
Duke University Medical Center, Durham, NC 27710, USA. morse004@mc.duke.edu
Whelan
Michael
M
D019496:Cancer Vaccines / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D054547:National Cancer Institute (U.S.); D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000517:prevention & control; D014481:United States
D019496:Cancer Vaccines